PHRHealthcare · Health Information ServicesThe 19 Wall Street analysts covering Phreesia, Inc. hold a median 12-month price target of $14 — +15.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 21 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Phreesia, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Quality (92): The business earns solid, repeatable profits on what it owns.
Momentum (10): The shares have been drifting down relative to others.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on PHR, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits +15.7% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 May 2026 | Truist Securities | Maintains | Hold | $11 → $12 |
| 28 May 2026 | Canaccord Genuity | Maintains | Buy | $22 → $16 |
| 28 May 2026 | Citigroup | Maintains | Neutral | $10 → $12 |
| 28 May 2026 | DA Davidson | Maintains | Buy | $14 |
| 20 May 2026 | Wells Fargo | Downgrade | Equal-Weight | — |
| 15 May 2026 | Barclays | Downgrade | Equal-Weight | — |
| 13 Apr 2026 | Keybanc | Maintains | Overweight | — |
| 1 Apr 2026 | Citizens | Downgrade | Market Perform | — |
| 31 Mar 2026 | Baird | Downgrade | Neutral | — |
| 31 Mar 2026 | BMO Capital | Maintains | Outperform | — |
| 31 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 31 Mar 2026 | Citigroup | Downgrade | Neutral | — |
| 31 Mar 2026 | JP Morgan | Downgrade | Neutral | — |
| 31 Mar 2026 | Needham | Maintains | Buy | — |
| 31 Mar 2026 | Stephens & Co. | Maintains | Overweight | — |
| 31 Mar 2026 | Truist Securities | Downgrade | Hold | — |
| 26 Mar 2026 | Wells Fargo | Maintains | Overweight | — |
| 24 Mar 2026 | Mizuho | Maintains | Outperform | — |
| 20 Feb 2026 | JP Morgan | Maintains | Overweight | — |
| 23 Jan 2026 | DA Davidson | Maintains | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. PHR appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 9% of US stocks
Cheaper than 61% of US stocks
Cheaper than 46% of US stocks
Cheaper than 13% of US stocks
Higher than 59% of US stocks
Higher than 51% of US stocks
Higher than 80% of US stocks
Higher than 55% of US stocks
Higher than 52% of US stocks
Higher than 49% of US stocks
Higher than 55% of US stocks
Higher than 94% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Phreesia, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Phreesia announced it will release its fiscal second quarter 2027 financial results after the close of market trading on Wednesday, Sept. 2, 2026.
Why it matters — A PHR watcher would care because this sets the date for the company's next scheduled earnings disclosure, marking the timing of its quarterly financial reporting.
Bernstein Liebhard LLP announced it is investigating potential breaches of fiduciary duty by certain directors and officers of Phreesia, Inc. The investigation aims to determine whether the company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
Why it matters — The investigation raises potential governance concerns about company leadership that could lead to legal action or affect shareholder confidence in PHR.
Bernstein Liebhard LLP is investigating potential breaches of fiduciary duty by certain directors and officers of Phreesia, Inc. The law firm is looking into whether the company's leadership fulfilled its obligations to shareholders and whether legal remedies may be available.
Why it matters — A shareholder investigation into potential breaches of fiduciary duty raises governance concerns for Phreesia investors and could lead to legal action against the company's leadership.
The 19 Wall Street analysts covering Phreesia, Inc. have a median 12-month price target of $14, with estimates ranging from $9 to $20. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 19 analysts covering Phreesia, Inc., 11 rate it a Buy, 8 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phreesia, Inc. 59 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 21 Aug 2026, Phreesia, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (92 of 100).
No one can know that. What the data says: the median 12-month target from 19 analysts implies +15.7% from the last close, and Ticker Nerd's factor model ranks Phreesia, Inc. 59 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Phreesia, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $20 over the next 12 months.
Phreesia, Inc. returned -57.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Phreesia Inc. is a healthcare technology company that provides patient intake and engagement solutions for medical practices.
The most recent item we track (Business Wire, 6 Aug 2026): "Phreesia Sets Release Date for Fiscal Second Quarter 2027 Results". Phreesia announced it will release its fiscal second quarter 2027 financial results after the close of market trading on Wednesday, Sept. 2, 2026.
Phreesia Inc. is a healthcare technology company that provides patient intake and engagement solutions for medical practices. Its primary function is to streamline the patient registration and intake process through digital tools, enhancing both operational efficiency and patient experience. Phreesia's platform offers a range of services, including appointment scheduling, insurance verification, and payment processing, helping healthcare providers optimize administrative workflows and focus more on patient care. By integrating with other health IT systems, Phreesia influences sectors such as outpatient clinics, specialty practices, and hospitals, ensuring seamless data capture and communication across healthcare teams. In the broader financial market, Phreesia Inc. plays a significant role by addressing the growing demand for digital transformation in the healthcare sector, which is driven by the need for efficiency and improved patient satisfaction. Established in 2005, Phreesia continues to innovate with solutions that cater to the evolving needs of healthcare providers in managing patient interactions and delivering quality care.
CEO Mr. Chaim Indig · 2,082 employees · United States · https://www.phreesia.com